SEE NEW DATA FROM THE RESPOND REAL-WORLD EFFECTIVENESS STUDY

Defend your patients' wounds between weekly debridements 
with PuraPly AM

Only PuraPly AM has the power of plus: The unique combination of native, cross-linked ECM + broad-spectrum PHMB that provides a sustained antimicrobial barrier to keep you in command of the healing environment all week long.1-3

ECM=extracellular matrix; PHMB=polyhexamethylene biguanide

NEW STUDY: PURAPLY AM SUPPORTED HEALING IN LARGE, DIFFICULT-TO-HEAL WOUNDS

The first prospective, large (N=307), multicenter (28 sites) cohort study of PuraPly AM showed that 86% of all PuraPly AM-treated wounds demonstrated improvement in the wound bed condition.4

WATCH A VIDEO SUMMARY OR SEE ALL OF THE DATA FROM THE RESPOND REAL-WORLD EFFECTIVENESS STUDY 
The opening frame from the RESPOND: Real-World Effectiveness Study of PuraPly AM on Wounds video

KEY BARRIERS 
TO HEALING

The inability and/or unwillingness of patients to adhere to treatment plans for chronic wounds can impede healing. However, healthcare studies show that patient adherence improves when treatments require less intervention.5

LEARN MORE ABOUT PATIENT NONCOMPLIANCE 

Excessive wound bioburden and biofilm trigger a continuous inflammatory response that stalls healing.6

LEARN MORE ABOUT BIOBURDEN & BIOFILM 

The inability and/or unwillingness of patients to adhere to treatment plans for chronic wounds can impede healing. However, healthcare studies show that patient adherence improves when treatments require less intervention.4

LEARN MORE ABOUT PATIENT NONCOMPLIANCE 

Excessive wound bioburden and biofilm trigger a continuous inflammatory response that stalls healing.6

LEARN MORE ABOUT BIOBURDEN & BIOFILM 

CHOOSE
NEXT-LEVEL
CONTROL WITH
PURAPLY AM

Early bioburden management with sharp debridement plus PuraPly AM puts you in immediate command of the healing environment.1,2,7-9

WHY PURAPLY AM 
PuraPly AM product shot

READY TO TAKE CONTROL OF 
THE HEALING ENVIRONMENT?

Talk to an Organogenesis Tissue Regeneration Specialist about the advanced antimicrobial barrier with native, cross-linked ECM + broad-spectrum PHMB.

Contact us

CONFIRMATION
OF CONTROL

Examine the scientific and real-world studies that demonstrate the effectiveness of PuraPly AM.

SCIENTIFIC EVIDENCE 
REAL-WORLD EVIDENCE 
Components that make up the Organogenesis Circle of Care program

Organogenesis' Circle of Care is a comprehensive program that provides the highest-quality customer service and reimbursement support. Our wide range of expertise includes:

VIEW ALL SERVICES 

Please refer to the PuraPly AM Instructions for Use for complete prescribing information.

REFERENCES:

  1. Data on file. PDR-0001. Organogenesis Inc.
  2. Data on file. PDR-0002. Organogenesis Inc.
  3. PuraPly Antimicrobial [package insert]. Canton, MA: Organogenesis Inc; 2020.
  4. Bain MA, et al. J Comp Eff Res. 2020:9(10):691-703. doi:10.2217/cer-2020-0058
  5. Atreja A, et al. MedGenMed. 2005;7(1):4.
  6. Frykberg RG, et al. Adv Wound Care. 2015;4(9):560-582.
  7. Hübner NO, et al. Skin Pharmacol Physiol. 2010;23(1 suppl):17-27.
  8. Brantley J, et al. Wounds Int. 2016;7(3):1-5.
  9. Gilbert P, et al. J Appl Microbiol. 2005;99(4):703-715.